U.S. markets closed

Sesen Bio, Inc. (SESN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.5902-0.0281 (-4.54%)
At close: 04:00PM EST
0.5925 +0.00 (+0.39%)
After hours: 05:26PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close0.6183
Bid0.5902 x 3200
Ask0.5986 x 900
Day's Range0.5850 - 0.6240
52 Week Range0.3650 - 0.9650
Avg. Volume1,039,655
Market Cap119.668M
Beta (5Y Monthly)0.86
PE Ratio (TTM)1.79
EPS (TTM)0.3300
Earnings DateFeb 27, 2023 - Mar 03, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est0.60
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for SESN

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Sesen Bio, Inc.
    Analyst Report: Pfizer Inc.Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor.
    Fair Value
    Economic Moat
View more
  • Business Wire

    Sesen Bio Receives NASDAQ Delisting Notice

    CAMBRIDGE, Mass., January 30, 2023--Sesen Bio, Inc. (Nasdaq: SESN) ("Sesen Bio" or the "Company") today announced that it has received notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") that, based upon the Company’s non-compliance with the $1.00 bid price requirement for continued listing on The Nasdaq Capital Market, the Company’s common stock is subject to delisting.

  • Business Wire

    Sesen Bio Reiterates Confidence that Pending Merger with Carisma is in Best Interests of Stockholders

    CAMBRIDGE, Mass., January 26, 2023--Sesen Bio, Inc. (Nasdaq: SESN) today issued the following statement reiterating the Company’s confidence in, and commitment to, the pending merger with Carisma Therapeutics Inc. (Carisma) in response to the release issued yesterday by Bradley Radoff and Michael Torok and their affiliates (collectively, the "Investor Group"):

  • Business Wire

    Investor Group Issues Letter to the Boards of Sesen Bio and Carisma Rejecting Their Apparent Attempt to Purchase Merger Support

    HOUSTON, January 25, 2023--Bradley L. Radoff and Michael Torok (together with their affiliates, the "Investor Group" or "we"), who own approximately 8.4% of the outstanding common stock of Sesen Bio, Inc. (Nasdaq: SESN) ("Sesen Bio"), today issued the following open letter to the Boards of Directors (collectively, the "Boards") of Sesen Bio and Carisma Therapeutics Inc. ("Carisma" and together with Sesen Bio, the "Companies"):